Given that the US continues making historic changes to its vaccine schedules, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on Covid shots throughout the global health crisis and has zeroed in on possible deaths after Covid vaccination in her brief position at the Food and Drug Administration.
Planned Shifts to Pediatric Vaccine Schedule
Health officials had intended to unveil radical changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would place the US out of step with a large portion of the international standard with insufficient data for improved outcomes. The planned update has been delayed until the coming year.
Rather than the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this year.
A New Direction at the Regulatory Body
This interim role might represent a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.
The new acting director has often pushed for halting specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.
So far public appearances, she has continued to focus on vaccines – usually the purview of Prasad, director of the FDA’s CBER – instead of medication approval.
Questions Over Expertise
The appointee has little discernible track record in pharmaceutical research, approval processes or administrative roles, which has been customary for past heads of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.
“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in managing a large organization. She lacks background in industry regulation.”
Past commissioners of the center would “understand legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Frankly, she lacks the type of experience that former directors who led CBER have had.”
CDER has an enormous portfolio at the agency, the former commissioner stated.
“Many people just zeroes in on the new drug program, but the generic program clears thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these need to be looked after,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”
Furthermore, a significant leadership component to the job, which manages over 5,000 personnel. “It’s a massive administrative position, if you do it right,” Woodcock concluded.
Agency Reaction and Controversial Policies
In response to concerns about Høeg’s credentials and whether this appointment represents increased cooperation among FDA leaders on vaccines, a press secretary stated that the “inquiries rely on flawed presumptions”.
“Her experience is consistent with the functions of her position,” the spokesperson stated, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.
In her interim role, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a disputed expedited therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”
In general, he said, “the FDA appears to be shifting towards more relaxed regulations of all drugs, with the exception of immunizations.”
Public Track Record on Immunizations
Concerning vaccines, Høeg has a clearer, if troubling, track record, critics said. She released a research paper using unverified crowd-sourced reports to determine the rate of heart inflammation following Covid immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are pose a greater threat than they are.
Part of her “policy goals” for the new administration included revising guidelines for recently developed shots and discontinuing “non-essential” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has according to sources proposed excluding adolescent males from receiving COVID-19 vaccines.
“She is an complete true believer who starts off with her preconceived notions and works backwards to retrofit the science in a very misleading, dishonest fashion,” Dr. Howard argued.
Taking Control and a “Campaign of Retribution”
Dr. Høeg aligned with other contrarians, {like|